Successful treatment of multiply relapsed lymphoma with rituximab as a single agent-Reference-Cited by-同舟云学术

Successful treatment of multiply relapsed lymphoma with rituximab as a single agent

Published:2010-05-05 Issue:2 Volume:55 Page:356-358
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Alasaad Tariq,Barr Ronald

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.22552/fullpdf

Reference5 articles.

1. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the Berlin-Frankfurt-Munster group;Burkhardt;J Clin Oncol,2009

2. Rituximab therapy in patients with relapsed aggressive B cell and mantle cell lymphoma;Borgerding;Ann Hematol,2009

3. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma;Tsirigotis;Ann Hematol,2009

4. Rituximab, gemicitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy;El Gnaoui;Ann Oncol,2007

5. Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20) a retrospective cohort analysis;Foran;Br J Haematol,2001

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Factors and Treatment Outcome of Relapsing and Refractory Pediatric Mature B-cell Non-Hodgkin Lymphoma, Children’s Cancer Hospital Egypt Experience;Journal of Pediatric Hematology/Oncology;2023-06-26

2. Long-Term Outcomes in Survivors of Childhood and Adolescent Non-Hodgkin Lymphoma;Non-Hodgkin's Lymphoma in Childhood and Adolescence;2019

3. Autologous peripheral blood stem cell transplantation in children and adolescents with non-Hodgkin lymphoma;Oncology Letters;2015-07-03

4. Rituximab used in three cases with relapsed non-Hodgkin’s lymphoma;Molecular and Clinical Oncology;2013-03-05

5. Anti-CD20 monoclonal antibody therapy and minimal residual disease status of T-cell/histiocyte-rich large B cell non-Hodgkin lymphoma;Pediatric Blood & Cancer;2011-04-07